PubMed · 8076262
The source did not provide an abstract. Follow the original record for more information.
Explore connections, maps & timelines
S N Breit, S C Thornton, R Penny. Lung involvement in scleroderma.. https://doi.org/10.1016/s0738-081x(94)90328-x
Cite the original work for its findings. Save a collection to share your selection of sources.
KEEP EXPLORING
OBJECTIVE: To determine if there is a difference between patients with bronchiolitis who are discharged from the emergency department (ED) but return requiring admission and those who do not return. DESIGN: Retrospective, case control study. SETTING: Tertiary care children's hospital emergency department. PARTICIPANTS: Fifty-seven study patients under one year of age with bronchiolitis seen from November 1991 to April 1993 who were discharged but returned requiring admission within 96 hours, and 124 controls, matched by diagnosis, who did not return. RESULTS: No differences were found between cases and controls in duration of illness (3.0 vs 3.7 days, P = 0.08), gestational age (39.3 vs 38.8 weeks, P = 0.32), chronologic age (20.9 vs 22.9 weeks, P = 0.31), respiratory rate (49.9 vs 48.0 respirations/ min, P = 0.18), presence of retractions (54.8 vs 54.4%, P = 0.97), oxygen saturation (SaO2; 97.6 vs 98.0%, P = 0.29), or number of nebulized beta-agonists administered in the ED (1.4 vs 1.2 P = 0.35). Cases had higher mean heart rates (HR) than controls (154.8 vs 148.8, P = 0.006). Patients with HR > 150 were more likely to return requiring admission (odds ratio = 2.45, 95% confidence intervals 1.2-4.9). However, only 36 of 57 patients who returned requiring admission had HR > 150 (sensitivity = 0.63), and 73 of 124 who did not return had HR < or = 150 (specificity = 0.59). None of the returns required admission to the intensive care unit, and their mean duration of admission was 59-hours. At the time of admission the cases had lower SaO2 (95.9 vs 97.7%, P = 0.001) and a higher frequency of retractions (83.3 vs 52.6%, P = 0.02) than when seen initially. CONCLUSIONS: Oxygen saturation and clinical assessment failed to differentiate between patients with bronchiolitis who returned requiring admission and patients who did not return.
OBJECTIVE: To review the clinical data detailing the use of respiratory syncytial virus immune globulin intravenous (RSV-IGIV) in infants and children. DATA SOURCES; A MEDLINE search (1990-1996) was used to identify all publications that dealt with RSV-IGIV clinical trials, pharmacology, and pharmacokinetics in infants and children. Bibliographies of articles were also used. STUDY SELECTION: All abstracts and clinical trials were reviewed. DATA EXTRACTION: Study design, population, efficacy, and safety data were retained. DATA SYNTHESIS: RSV-IGIV is an immunoglobulin product with serum neutralizing titers against RSV. It has been shown to reduce hospital stay, admissions, intensive care unit admissions, and mechanical ventilation days in infants and children with RSV pneumonia or bronchiolitis who are younger than 24 months of age and were born prematurely, or have bronchopulmonary dysplasia. RSV-IGIV is well tolerated by infants and children. CONCLUSIONS: RSV-IGIV is an effective prophylactic agent against serious RSV disease in select groups of infants and children.
OBJECTIVES: To evaluate the efficacy of high-titer intravenous respiratory syncytial virus immune globulin (RSVIG) in the treatment of children at high risk for severe RSV infection who were hospitalized with proven RSV. METHODS: Infants and young children younger than 2 years with bronchopulmonary dysplasia, chronic lung disease, congenital heart disease, or prematurity (<32 weeks' gestational age), hospitalized with a history of lower respiratory tract infection (LRI) of less than 4 days, were enrolled in this study. Patients were randomized in a blinded fashion to receive either 1500 mg/kg RSVIG or placebo in equal volumes. They were evaluated daily for safety and respiratory scores and for RSV nasal shedding. RESULTS: One hundred seven high-risk children were randomized--54 in the RSVIG group and 53 in the placebo group. Of these children, 51 in each group were considered evaluable. Children with pulmonary disease, congenital heart disease, or prematurity were equally distributed between the two treatment groups. However, two important differences were found in baseline variables between the two groups: there were more patients in the placebo group who had histories of previous LRI and there was a trend toward more severe disease at study entry in the RSVIG group. This was manifested by a higher entry respiratory score in the RSVIG group than in the placebo group (3.4 +/- 0.2 vs 3.1 +/- .01). A higher proportion of children in the RSVIG group (47%) than in the placebo group (28%) required intensive care at entry and mechanical ventilation at study entry (31% RSVIG-treated vs 18% placebo-treated patients). No significant difference was found between groups in the mean unadjusted duration of hospitalization (RSVIG group, 9.10 +/- 1.18 days; control group, 8.17 +/- 1.08 days). When the mean was adjusted for entry respiratory score, likewise, no difference was observed between each group (8.41 +/- 0.97 vs 8.89 +/- .99 days). The lack of efficacy observed in the study primary endpoint was observed in all diagnostic groups. No differences between the RSVIG and placebo groups were observed in the following secondary endpoints: duration of intensive care unit stay, duration of intensive care unit stay for RSV, mechanical ventilation, or supplemental oxygen. No significant differences in adverse events were reported in the RSVIG group (16 children) when compared with the control group (10 children). CONCLUSION: RSVIG treatment was safe but not efficacious in the treatment of children with bronchopulmonary dysplasia, congenital heart disease, or premature gestation who were hospitalized with RSV LRI.